Search - tctmd.com

Displaying 21 - 40 of 40

Sort: Relevancy | Date

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Conference News ESC 2021

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

Yael L. Maxwell

September 03, 2021

News Conference News ESC 2021

AV Junction Ablation Plus CRT Cuts Deaths in Permanent AF Subset

Todd Neale

September 01, 2021

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

Todd Neale

August 27, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Conference News ESC 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Michael O'Riordan

September 01, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

Todd Neale

August 31, 2020

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

Todd Neale

August 27, 2018

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

Shelley Wood

August 20, 2018

News Conference News ESC 2016

ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH

Michael O'Riordan

August 28, 2016

News Conference News ESC 2016

Another Meeting, Another Mesenchymal Stem Cell Study (or Two), With Mixed Results

Shelley Wood

August 28, 2016

Advertisement

What’s Going to Be Hot at ESC 2022?

In HFrEF, AI Shows Promise For Predicting Beta Blocker Response

AV Junction Ablation Plus CRT Cuts Deaths in Permanent AF Subset

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Dapagliflozin Wins in Patients With CKD

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH

Another Meeting, Another Mesenchymal Stem Cell Study (or Two), With Mixed Results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content